**Formulations**

- **Tablet, Oral:**
- 1 mg, 2 mg, 4 mg

- **Tablet, Oral, as mesylate:**
- 8 mg

- **Tablet Extended-Release 24 Hour, Oral:**
- 4 mg, 8 mg 
- As with all extended-release formulations, this formulation should not be crushed to pass through a nasogastric, orogastric, or PEG tube.

**Dosing**

- **Benign Prostatic Hyperplasia**
- Oral Immediate Release: Initiate at 1 mg once daily. The dose may be titrated up at 1- to 2-week intervals up to a maximum dose of 8 mg once daily. This titration should take place by doubling the dose while monitoring for response and tolerability. 
- Oral Extended Release: Initiate at 4 mg once daily. The dose may be titrated up at 3- to 4-week intervals up to a maximum dose of 8 mg once daily. The clinician should titrate by doubling the dose while monitoring for response and tolerability. 
- The reinitiation of Therapy: If therapy discontinues for several days, reinitiate therapy at the initial dose and titrate according to the initial dose regimen.

- **Hypertension**
- Oral Immediate Release: Initiate at 1 mg once daily. The dose may be titrated up to 16 mg once daily; this should occur while monitoring for response and tolerability.